Cerebral/Cortical Visual Impairment Classification and Categorization Using Eye Tracking Measures of Oculomotor Function

IF 3.2 Q1 OPHTHALMOLOGY
Melinda Y. Chang MD , Mark S. Borchert MD
{"title":"Cerebral/Cortical Visual Impairment Classification and Categorization Using Eye Tracking Measures of Oculomotor Function","authors":"Melinda Y. Chang MD ,&nbsp;Mark S. Borchert MD","doi":"10.1016/j.xops.2025.100728","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Cerebral/cortical visual impairment (CVI) is a leading cause of pediatric visual impairment and is frequently associated with abnormal ocular motility. Eye tracking has previously been used to characterize oculomotor function in CVI. The purpose of this study was to evaluate the utility of eye tracking in diagnosis, categorization, and prognostication of CVI.</div></div><div><h3>Design</h3><div>Prospective longitudinal study.</div></div><div><h3>Participants</h3><div>Thirty-nine children with CVI and 41 age-matched controls.</div></div><div><h3>Methods</h3><div>Children with CVI underwent 4 eye tracking sessions over 1 year, and age-matched controls completed 1 eye tracking session. Fixations and saccades were labeled by the eye tracking software and used to compute 9 oculomotor features. In children with CVI, unsupervised data-driven clustering analysis using these 9 features was performed to identify 3 CVI eye tracking oculomotor groups. Clinical and demographic characteristics of eye tracking oculomotor groups were compared.</div></div><div><h3>Main Outcome Measures</h3><div>(1) Area under the curve (AUC) for eye tracking oculomotor features in classifying patients with CVI and controls; (2) differences between 3 CVI eye tracking oculomotor groups on clinical and demographic characteristics; and (3) change in visual acuity (VA) over 1 year in 3 CVI eye tracking oculomotor groups.</div></div><div><h3>Results</h3><div>Six oculomotor features (fixation and saccade latency, frequency, and off-screen proportion) had an AUC ≥0.90 in classifying children with CVI and controls (<em>P</em> &lt; 0.0001). Cerebral/cortical visual impairment eye tracking oculomotor groups had significantly different VA (<em>P</em> &lt; 0.0001) and change in VA over 1 year (<em>P</em> = 0.049). Patients in group B, who had the greatest improvement in VA, were younger and had higher rates of term hypoxic ischemic encephalopathy.</div></div><div><h3>Conclusions</h3><div>Eye tracking measures of oculomotor function accurately distinguish between children with CVI and age-matched controls. Clustering analysis revealed 3 CVI eye tracking oculomotor groups with prognostic significance. Eye tracking shows promise as an objective, quantitative measure of oculomotor function in CVI that may in future be useful in both clinical practice (for longitudinal assessment, prognostication, and guiding individualized interventions) and research (as an outcome measure or method to stratify patients in clinical trials).</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":74363,"journal":{"name":"Ophthalmology science","volume":"5 3","pages":"Article 100728"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666914525000260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Cerebral/cortical visual impairment (CVI) is a leading cause of pediatric visual impairment and is frequently associated with abnormal ocular motility. Eye tracking has previously been used to characterize oculomotor function in CVI. The purpose of this study was to evaluate the utility of eye tracking in diagnosis, categorization, and prognostication of CVI.

Design

Prospective longitudinal study.

Participants

Thirty-nine children with CVI and 41 age-matched controls.

Methods

Children with CVI underwent 4 eye tracking sessions over 1 year, and age-matched controls completed 1 eye tracking session. Fixations and saccades were labeled by the eye tracking software and used to compute 9 oculomotor features. In children with CVI, unsupervised data-driven clustering analysis using these 9 features was performed to identify 3 CVI eye tracking oculomotor groups. Clinical and demographic characteristics of eye tracking oculomotor groups were compared.

Main Outcome Measures

(1) Area under the curve (AUC) for eye tracking oculomotor features in classifying patients with CVI and controls; (2) differences between 3 CVI eye tracking oculomotor groups on clinical and demographic characteristics; and (3) change in visual acuity (VA) over 1 year in 3 CVI eye tracking oculomotor groups.

Results

Six oculomotor features (fixation and saccade latency, frequency, and off-screen proportion) had an AUC ≥0.90 in classifying children with CVI and controls (P < 0.0001). Cerebral/cortical visual impairment eye tracking oculomotor groups had significantly different VA (P < 0.0001) and change in VA over 1 year (P = 0.049). Patients in group B, who had the greatest improvement in VA, were younger and had higher rates of term hypoxic ischemic encephalopathy.

Conclusions

Eye tracking measures of oculomotor function accurately distinguish between children with CVI and age-matched controls. Clustering analysis revealed 3 CVI eye tracking oculomotor groups with prognostic significance. Eye tracking shows promise as an objective, quantitative measure of oculomotor function in CVI that may in future be useful in both clinical practice (for longitudinal assessment, prognostication, and guiding individualized interventions) and research (as an outcome measure or method to stratify patients in clinical trials).

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmology science
Ophthalmology science Ophthalmology
CiteScore
3.40
自引率
0.00%
发文量
0
审稿时长
89 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信